Publications – KalVista Pharmaceuticals

Patients & Caregivers
- About HAE
Healthcare Professionals
Clinical Trials
Presentations & Publications
Investors & News

About
Science
Pipeline
Careers
- Careers
- Job Openings
Contact

Presentations & Publications

We are committed to rigorous science and innovative drug development, and we are excited to share our ongoing progress.

Explore Our
Virtual Medical Booth

Filtered (2)

Filters

Reset all ×
HAE burden of treatment data ×
2021 ×

Apply Reset

Topic

Sebetralstat (KVD900) in HAE clinical program (0)
HAE attack journey data (0)
HAE burden of treatment data (2)
Oral Factor XIIa inhibitor (0)

Forum

Medical Meeting (2)
Publication (0)

Year

2024 (5)
2023 (13)
2022 (1)
2021 (2)
2020 (0)
2019 (0)
2018 (0)
2017 (0)
2016 (0)
2015 (0)
2013 (0)
2011 (0)
2010 (0)
2009 (0)
2008 (0)
2007 (0)

Show (2)

Cancel

Apply Reset

Showing 2 out of 2

Prevalence of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physicians

Riedl MA, Danese M, Danese S, Ulloa J, and Maetzel A

EAACI 2021

Current management of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physicians

Riedl MA, Danese M, Danese S, Ulloa J, and Maetzel A

EAACI 2021

About

Management team

Board of Directors

Science

Pipeline

Sebetralstat

Oral Factor XIIa Inhibitor

Careers

Job Openings

Contact

KalVista Terms of Use Privacy Policy